Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01160263 | Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls | PHASE3 | COMPLETED | 16 | — | — | Oct 1, 2012 | Oct 1, 2014 | May 13, 2015 | 2 | France |
| Arm | Type | Description |
|---|---|---|
| patients without stiffness | OTHER | - |
| patients with pyramidal stiffness | OTHER | - |
| patients with mixed stiffness | OTHER | - |
| Name | Type | Description |
|---|---|---|
| SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM | DRUG | 123 I-FP-CIT (DATSCAN) : 185 MBq (5 mCi), 2,5 ml will be injected via an arm intravenous catheter. 123I-ADAM:185 MBq,5 ml will be injected via an arm intravenous catheter. |
Inclusion Criteria: 1. Patients (men or women) * between 39 (exclusive) and 66 (inclusive) years old * with a sporadic ALS, defined, probable or laboratory possible * with a disease duration between 3 months (inclusive) and 5 years (exclusive) * treated with rilutek at 100 mg/ day sinc...